User banner image
User avatar
  • admin

Posts

PharmAust affirms corporate strategy with name change to Neurizon Therapeutics

MELBOURNE, Australia, Oct. 16, 2024 /PRNewswire/ — Neurizon Therapeutics Limited (ASX: NUZ) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases,...

Prime Matter Labs Names Four Industry Leaders to New Advisory Board

Board to Include Leaders with Experience at Google, P&G, KDC/One, and Red Antler NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — Prime Matter Labs (PML),...

Glycolic Acid Market to Surpass USD 782.9 Million by 2034, Driven by Growing Demand in Skincare and Industrial Applications | Future Market Insights, Inc.

The global Glycolic Acid Market is projected to expand from USD 499.4 million in 2024 to USD 782.9 million by 2034, with a compound annual...

Noom Strengthens Healthcare Team by Adding Women’s Health Experts

Julia Edelman, MD, joins as Executive Director of Women’s Health and Karen Mann, MD, joins Noom as Medical Director NEW YORK, Oct. 15, 2024 (GLOBE...

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week

WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative,...

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform...

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that...

LONGi unveils Hi-MO X10 module featuring HPBC 2.0 cell technology at Rolex Shanghai Masters

SHANGHAI, Oct. 15, 2024 /PRNewswire/ — LONGi has officially launched its new generation distributed module product Hi-MO X10 at the Rolex Shanghai Masters. The module,...

Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

After 24 weeks of treatment in patients with Type 2 diabetes, the bi-weekly GLP-1 receptor agonist GZR18 injection showed superior efficacy in lowering HbA1c and...